Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Rain
Toggle navigation
Menu
Subscribe
Home
News
Local News
Sports
Entertainment
Obituaries
Photos
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Ampio Pharmaceuticals
(NY:
AMPE
)
1.740
USD
-0.060 (-3.33%)
Official Closing Price
Updated: 8:00 PM EST, Jan 25, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Ampio Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled
January 14, 2021
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced its...
From
PR Newswire
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
January 04, 2021
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced an update...
From
PR Newswire
Thinking about buying stock in BioNano Genomics, Ampio Pharmaceuticals, TRACON Pharmaceuticals, eMagin Corp, or Matinas BioPharma?
December 31, 2020
InvestorsObserver issues critical PriceWatch Alerts for BNGO, AMPE, TCON, EMAN, and MTNB.
From
PR Newswire
Ampio Receives feedback from the FDA on Ampio's Proposed Modifications to the special protocol assessment for Ampion treatment of severe Osteoarthritis of the knee
December 29, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today it has...
From
PR Newswire
Thinking about buying stock in CASI Pharmaceuticals, FuelCell Energy, Ampio Pharmaceuticals, Mohawk Group, or Perion Network?
December 23, 2020
InvestorsObserver issues critical PriceWatch Alerts for CASI, FCEL, AMPE, MWK, and PERI.
From
PR Newswire
Thinking about buying stock in CNS Pharmaceuticals, DermTech, Ampio Pharmaceuticals, Surface Oncology, or Amyris?
December 18, 2020
InvestorsObserver issues critical PriceWatch Alerts for CNSP, DMTK, AMPE, SURF, and AMRS.
From
PR Newswire
Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion
December 17, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it has...
From
PR Newswire
Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals?
December 14, 2020
InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX.
From
PR Newswire
Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?
December 11, 2020
InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO.
From
PR Newswire
Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion
December 10, 2020
Agreements made with (i) Oldest and one of the top children's hospitals in the United States and (ii) Prominent Research Scientist at Vanderbilt University Medical Center
From
PR Newswire
Pelareorep Along With Checkpoint Inhibitors Proving Critically Important for Early Stage Breast Cancer
December 09, 2020
Tags
Featured News
From
FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Pelareorep Along With Checkpoint Inhibitors Proving Critically Important for Early Stage Breast Cancer
December 09, 2020
Financialnewsmedia.com News Commentary
From
PR Newswire
Thinking about buying stock in Pfizer, Ampio Pharmaceuticals, Aerpio Pharmaceuticals, Electrameccanica Vehicles, or United Airlines?
December 09, 2020
InvestorsObserver issues critical PriceWatch Alerts for PFE, AMPE, ARPO, SOLO, and UAL.
From
PR Newswire
Ampio Pharmaceuticals, Inc. to Host its Annual Meeting on December 12, 2020
December 08, 2020
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today that the Company...
From
PR Newswire
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress
December 02, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its...
From
PR Newswire
Ampio Updates Regulatory and Clinical Trial Events
November 25, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today the...
From
PR Newswire
Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress
November 17, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the...
From
PR Newswire
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress
November 10, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the...
From
PR Newswire
Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results
November 05, 2020
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, today, at 4:30pm EST, will...
From
PR Newswire
Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th
November 02, 2020
Will Provide Business Update and Review Third Quarter Financial Results
From
PR Newswire
Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress
October 28, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today the...
From
PR Newswire
Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics in Development"
October 27, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it will...
From
PR Newswire
Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities
October 26, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the...
From
PR Newswire
Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation
October 08, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the...
From
PR Newswire
Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer
September 29, 2020
Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today...
From
PR Newswire
Thinking about buying stock in Onconova Therapeutics, Norwegian Cruise Line, Ampio Pharmaceuticals, Delta Air Lines, or Plug Power?
September 21, 2020
InvestorsObserver issues critical PriceWatch Alerts for ONTX, NCLH, AMPE, DAL, and PLUG.
From
PR Newswire
FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress
September 21, 2020
From
PR Newswire
Ampion Phase I COVID-19 Patient Trial Results Featured on FOX News (Video)
September 14, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that...
From
PR Newswire
Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients
September 09, 2020
- Ampion-treated patients showed improvement from severe disease/hospitalization to uninfected/ambulatory on the ordinal scale
From
PR Newswire
Ampio Announces Enrollment Completion for Intravenous ("IV") COVID-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee ("OAK") Clinical Trial
September 04, 2020
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following:
From
PR Newswire
< Previous
1
2
3
4
5
6
7
8
9
...
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.